TNFRSF11A and colorectal carcinoma: Therefore, the downregulation of OPG can be a favorable biomarker for CRC liver metastasis, and the inhibition of the RANKL-RANK pathway by OPG or anti-RANKL antibodies in such patients can provide a new therapeutic strategy for CRC liver metastasis.